Neuronetics, Inc. (STIM): Entry into a Material Definitive Agreement

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Neuronetics Announces Proposed Public Offering of Common Stock MALVERN, Pa., November 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar ® TMS technology an

Event · Offering · proposed
Instrument
common stock
Use of proceeds
prepayment of a portion of the outstanding term loans under the Perceptive Facility
Also in this documentDebt financing

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 12, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$STIM
Bearish
high confidence
Mentioned
$STIM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STIMBearishMed
01

Why it matters

The capital raise could strengthen the balance sheet but may temporarily depress the share price.

02

Market read

Primary disclosure of a material equity offering; relevant for traders with exposure to STIM.

03

What to watch

The amendment to the credit facility may improve liquidity, reducing near‑term financial risk.

Relevance 6/10Novelty 8/10Timing: today

Background

Neuronetics is a provider of TMS therapy and operates a network of psychiatry clinics.

Company-level read

Ticker impact

$STIMBearishHigh confidence
Context

Neuronetics filed an 8‑K announcing an underwritten public offering of its common stock, the first disclosure of this capital raise.

Expected impact

downward pressure as the market prices in dilution risk

Evidence & confidence

Primary disclosure of a material equity raise typically leads to short‑term share price weakness.

Market effects

May affect other mental‑health and med‑tech firms as investors reassess financing needs.

Limited to U.S. markets where the stock trades.

Low, as the offering is company‑specific.

Counterpoint

If the proceeds fund high‑margin growth initiatives, the dilution could be offset by future earnings upside.

Key entities

  • Neuronetics, Inc.

    Issuer of the public offering.

  • William Blair

    Lead bookrunning manager for the offering.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.